KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (2016 - 2026)

Supernus Pharmaceuticals has reported Shares Outstanding over the past 15 years, most recently at $57.5 million for Q4 2025.

  • Quarterly Shares Outstanding rose 3.08% to $57.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.5 million through Dec 2025, up 3.08% year-over-year, with the annual reading at $57.5 million for FY2025, 3.08% up from the prior year.
  • Shares Outstanding was $57.5 million for Q4 2025 at Supernus Pharmaceuticals, up from $57.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $57.5 million in Q4 2025 and troughed at $53.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $54.6 million (2023), against an average of $54.7 million.
  • Year-over-year, Shares Outstanding rose 0.65% in 2022 and then rose 3.44% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $53.3 million in 2021, then rose by 1.87% to $54.3 million in 2022, then grew by 0.87% to $54.7 million in 2023, then rose by 1.86% to $55.7 million in 2024, then increased by 3.08% to $57.5 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Shares Outstanding are $57.5 million (Q4 2025), $57.1 million (Q3 2025), and $56.1 million (Q2 2025).